Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 8/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2384392 | 0.98 | MAPT (0.49) | MAPTRXFP1THRBLMNATP53 | |
| SCHEMBL4793026 | 0.79 | RXFP1 (0.48) | MAPTRXFP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2382218 | 0.78 | RXFP1 (0.47) | MAPTRXFP1MEN1KMT2A | |
| SCHEMBL4774449 | 0.77 | L3MBTL1 (0.58) | MAPTRXFP1LMNAMEN1KMT2A | |
| SCHEMBL1339473 | 0.76 | KMT2A (0.50) | MAPTMEN1KMT2A | |
| SCHEMBL29769204 | 0.75 | MAPT (0.57) | MAPTRXFP1THRBLMNATP53 | |
| SCHEMBL5985980 | 0.75 | MAPT (0.57) | MAPTRXFP1THRBLMNATP53 | |
| Hydrochloric Acid SCHEMBL2384487 | 0.75 | L3MBTL1 (0.56) | MAPTRXFP1LMNAMEN1KMT2A | |
| SCHEMBL1338266 | 0.75 | CDC7 (0.40) | CYP2A6 | |
| Hydrochloric Acid SCHEMBL1339416 | 0.74 | KMT2A (0.48) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012991-B2 | 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate | SANOFI-AVENTIS (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| US-7390818-B2 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-06-24 | — | — | US | disclosed |
| EP-1556382-B1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-28 | — | — | EP | disclosed |
| EP-1556380-B1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | disclosed |
| EP-1556382-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| EP-1556380-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041817-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037821-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | PNPO, PDXK, PLPBP | MAPT 1995/4885RXFP1 1345/4885THRB 637/4885 |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | PNPO, PLPBP, DPYD | MAPT 2131/4885RXFP1 2516/4885THRB 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.